- Expands Illumina’s Oncology Offerings for NextSeq™ 550Dx with a Companion Diagnostic Version of...
STAMFORD, Conn., April 04, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a...
Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
STAMFORD, Conn., March 06, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a...
Table of Contents UNITED STATES SECURITIES AND...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC...
– Larotrectinib Rolling NDA Submission on Track for Completion in March – – LOXO-292 Phase 1 Clinical...
STAMFORD, Conn., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical...
Bayer Announces Publication of Larotrectinib Data in The New England Journal of Medicine - Larotrectinib...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.